UA117686C2 - Солі 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1r)-4-(трифторометил)-2,3-дигідро-1н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислоти - Google Patents
Солі 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1r)-4-(трифторометил)-2,3-дигідро-1н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислотиInfo
- Publication number
- UA117686C2 UA117686C2 UAA201606202A UAA201606202A UA117686C2 UA 117686 C2 UA117686 C2 UA 117686C2 UA A201606202 A UAA201606202 A UA A201606202A UA A201606202 A UAA201606202 A UA A201606202A UA 117686 C2 UA117686 C2 UA 117686C2
- Authority
- UA
- Ukraine
- Prior art keywords
- dihydro
- salts
- tetrahydropyrimidin
- trifluormethyl
- benzoxazol
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- JDARDSVOVYVQST-MRXNPFEDSA-N 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxylic acid Chemical class C1CC(C(=CC=C2)C(F)(F)F)=C2[C@@H]1N(C1=O)C(=O)C(C(O)=O)=CN1C1=CC=C2N(C)C(=O)OC2=C1 JDARDSVOVYVQST-MRXNPFEDSA-N 0.000 title 1
- -1 amino acid salts Chemical class 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 | ||
| PCT/EP2014/073801 WO2015067652A1 (de) | 2013-11-08 | 2014-11-05 | Salze von 1 -(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1 r)-4-(trifluormethyl)-2,3-dihydro-1h-inden-1 -yl]-1,2,3,4-tetrahydropyrimidin-5-carbonsäure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA117686C2 true UA117686C2 (uk) | 2018-09-10 |
Family
ID=49552231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201606202A UA117686C2 (uk) | 2013-11-08 | 2014-11-05 | Солі 1-(3-метил-2-оксо-2,3-дигідро-1,3-бензоксазол-6-іл)-2,4-діоксо-3-[(1r)-4-(трифторометил)-2,3-дигідро-1н-інден-1-іл]-1,2,3,4-тетрагідропіримідин-5-карбонової кислоти |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9926305B2 (https=) |
| EP (1) | EP3066097B1 (https=) |
| JP (1) | JP6446051B2 (https=) |
| KR (1) | KR102351418B1 (https=) |
| CN (1) | CN105658647B (https=) |
| AP (1) | AP2016009181A0 (https=) |
| AU (1) | AU2014345599B2 (https=) |
| BR (1) | BR112016010253A8 (https=) |
| CA (1) | CA2929780C (https=) |
| CL (1) | CL2016001096A1 (https=) |
| CY (1) | CY1119520T1 (https=) |
| DK (1) | DK3066097T3 (https=) |
| EA (1) | EA033132B1 (https=) |
| ES (1) | ES2645480T3 (https=) |
| HR (1) | HRP20171603T1 (https=) |
| HU (1) | HUE035021T2 (https=) |
| IL (1) | IL245407B (https=) |
| LT (1) | LT3066097T (https=) |
| MA (1) | MA39020A1 (https=) |
| ME (1) | ME02907B (https=) |
| MX (1) | MX366848B (https=) |
| MY (1) | MY190108A (https=) |
| NO (1) | NO3066097T3 (https=) |
| PH (1) | PH12016500853B1 (https=) |
| PL (1) | PL3066097T3 (https=) |
| PT (1) | PT3066097T (https=) |
| RS (1) | RS56509B1 (https=) |
| SA (1) | SA516371082B1 (https=) |
| SI (1) | SI3066097T1 (https=) |
| TN (1) | TN2016000170A1 (https=) |
| UA (1) | UA117686C2 (https=) |
| WO (1) | WO2015067652A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| WO2018197333A1 (en) * | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| CN114671856B (zh) * | 2020-12-25 | 2023-10-20 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2023194222A1 (en) * | 2022-04-05 | 2023-10-12 | Socpra Sciences Santé Humaines S.E.C. | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4175887B2 (ja) * | 2000-10-19 | 2008-11-05 | 日本化薬株式会社 | 新規血管狭窄治療剤または予防剤 |
| AT511788A1 (de) | 2011-07-29 | 2013-02-15 | Georg Dr Gaul | Vorrichtung zur vorgebbaren anordnung eines stents |
| JP6549376B2 (ja) * | 2012-03-05 | 2019-07-24 | グラタク テクノロジーズ ピーティーワイ リミテッド | 栄養補助食品 |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| HK1224288A1 (zh) * | 2013-11-08 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
-
2014
- 2014-11-05 CN CN201480057947.4A patent/CN105658647B/zh active Active
- 2014-11-05 BR BR112016010253A patent/BR112016010253A8/pt not_active Application Discontinuation
- 2014-11-05 ME MEP-2017-249A patent/ME02907B/me unknown
- 2014-11-05 NO NO14793565A patent/NO3066097T3/no unknown
- 2014-11-05 DK DK14793565.4T patent/DK3066097T3/da active
- 2014-11-05 UA UAA201606202A patent/UA117686C2/uk unknown
- 2014-11-05 MA MA39020A patent/MA39020A1/fr unknown
- 2014-11-05 CA CA2929780A patent/CA2929780C/en active Active
- 2014-11-05 SI SI201430450T patent/SI3066097T1/sl unknown
- 2014-11-05 EA EA201600381A patent/EA033132B1/ru not_active IP Right Cessation
- 2014-11-05 US US15/035,165 patent/US9926305B2/en active Active
- 2014-11-05 WO PCT/EP2014/073801 patent/WO2015067652A1/de not_active Ceased
- 2014-11-05 RS RS20171063A patent/RS56509B1/sr unknown
- 2014-11-05 AP AP2016009181A patent/AP2016009181A0/en unknown
- 2014-11-05 LT LTEP14793565.4T patent/LT3066097T/lt unknown
- 2014-11-05 PL PL14793565T patent/PL3066097T3/pl unknown
- 2014-11-05 AU AU2014345599A patent/AU2014345599B2/en active Active
- 2014-11-05 ES ES14793565.4T patent/ES2645480T3/es active Active
- 2014-11-05 JP JP2016551038A patent/JP6446051B2/ja active Active
- 2014-11-05 MY MYPI2016701615A patent/MY190108A/en unknown
- 2014-11-05 KR KR1020167011771A patent/KR102351418B1/ko active Active
- 2014-11-05 HU HUE14793565A patent/HUE035021T2/en unknown
- 2014-11-05 MX MX2016005971A patent/MX366848B/es active IP Right Grant
- 2014-11-05 EP EP14793565.4A patent/EP3066097B1/de active Active
- 2014-11-05 TN TN2016000170A patent/TN2016000170A1/en unknown
- 2014-11-05 HR HRP20171603TT patent/HRP20171603T1/hr unknown
- 2014-11-05 PT PT147935654T patent/PT3066097T/pt unknown
-
2016
- 2016-05-01 IL IL24540716A patent/IL245407B/en active IP Right Grant
- 2016-05-06 PH PH12016500853A patent/PH12016500853B1/en unknown
- 2016-05-06 CL CL2016001096A patent/CL2016001096A1/es unknown
- 2016-05-08 SA SA516371082A patent/SA516371082B1/ar unknown
-
2017
- 2017-10-25 CY CY20171101110T patent/CY1119520T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015003653A (es) | Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj. | |
| EA201592200A1 (ru) | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b | |
| NZ710111A (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
| PH12012500622A1 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| PE20140966A1 (es) | Quinazolincarboxamida azetidinas | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| BR112014028042A2 (pt) | inibidores de nampt | |
| MX342924B (es) | Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas. | |
| CY1125224T1 (el) | Κρυσταλλικες μορφες 1-(3-τριτ-βουτυλο-1-ρ- τολυλο-1η-πυραζολ-5-υλο)-3-(5-φθορο-2-(1-(2- υδροξυαιθυλ)-ινδαζολ-5-υλοξυ)βενζυλ)ουριας υδροχλωρικη | |
| PH12016500853A1 (en) | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid | |
| EA201490045A1 (ru) | Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении | |
| EA201391026A1 (ru) | Кристаллическое производное оксазина и его применение в качестве ингибитора bace | |
| EA201491878A1 (ru) | Замещенные ксантиновые производные | |
| EA201270176A1 (ru) | Производные тазаротена | |
| AU2019268209A1 (en) | Compounds for the treatment of seizures and other central nervous system disorders and conditions | |
| ECSP13013043A (es) | Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma | |
| MX2015006807A (es) | Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas. | |
| TH1601002185A (th) | เกลือแบบใหม่ของ 1-(3-เมธิล-2-ออกโซ-2,3-ไดไฮโดร-1,3-เบนซอกซาโซล-6-อิล)-2,4- ไดออกโซ-3-[(1r)-4-(ไตรฟลูออโรเมธิล)-2,3-ไดไฮโดร-1h-อินดิน-1-อิล]-1,2,3,4- เตตระไฮโดรไพริมิดีน-5-คาร์บอกซิลิกแอซิดและการใช้เกลือดังกล่าว | |
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| PL410369A1 (pl) | Nowe pochodne peptydowe, sposób ich otrzymywania, kompozycja farmaceutyczna, kompozycja dezynfekująca oraz zastosowanie i zestaw | |
| IN2014MU01178A (https=) | ||
| EA201790231A1 (ru) | Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза | |
| IN2014MU01179A (https=) | ||
| MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |